Alisertib
HER2/Neu Negative
Mayo ClinicSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
192 Active assets in the HER2/Neu Negative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Helwan University | Phase 2 | BBB |
EXEMESTANE National Cancer Institute (NCI) | Phase 4 | BBB |
Pembrolizumab UNC Lineberger Comprehensive Cancer Center | Phase 2 | BBB |
Atezolizumab TransThera Sciences (Nanjing), Inc. | Phase 2 | BB |
Inno-206 Roswell Park Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →